ArticlePaediatrics & child health2025
Blister packaging to support warfarin adherence in paediatric patients: A pilot retrospective study.
Article in Paediatrics & child health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Warfarin continues to be used in children for specific indications. Children must test their blood regularly and adherence to the medication routine can be highly challenging. Warfarin nonadherence has the potential for significant complications. Blister packaging (BP) is not commonly applied to warfarin therapy due to frequent dose titrations however BP may be useful in improving adherence. Objective: To evaluate the efficacy of BP warfarin to determine its impact on outpatient management. Methods: Retrospective chart review of children aged from 18 months to 18 years with suboptimal adherence transitioned to BP between 2021 and 2023. Data collected included international normalized ratio (INR) reminders, missed doses, bleeding or thrombotic events, and INRs for 6 months pre-/post-BP. Time in therapeutic range (TTR) analysis as a measure of safety and efficacy was used. Results: Eleven charts were reviewed. Mean and median age were 11 and 9 years, respectively (4 to 17 range), nine female and two male. International normalized ratio reminders required decreased 30% pre-/post-BP initiation 84 (mean 7.6, range 0 to 18/child) and 59 (mean 5.4; range 1 to 15/child), respectively. Missed doses decreased by 20% pre-/post-BP 35 (mean 3.2; range 0 to 10) and 29 (mean 2.6; range 0 to 10), respectively. The TTR increased by a median of 11.61% from pre to post. This difference was not statistically significant ( Conclusion: This study demonstrates that BP is a viable option that supports warfarin management. Caregivers described BP as beneficial with a trend to increased TTR and a decrease in healthcare provider workload.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.